Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231

Conclusion: ZOL reduces the motility and cellular velocity of breast cancer cells in vitro. The reduced mobility might slow down or even stop metastasis, which is a known result of adjuvant ZOL therapy in breast cancer patients. In vivo studies are warranted to evaluate the impact of the reduced motility on the metastatic cascade.

Source: In Vivo - November 3, 2016 Category: Research Authors: BUHLER, H., HOBERG, C., FAKHRIAN, K., ADAMIETZ, I. A. Tags: Experimental Studies Source Type: research